Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

To be considered for this study, you would need to be 18 years old or older and have a confirmed diagnosis of multiple myeloma. Importantly, your multiple myeloma should have either come back or not responded to at least three different types of previous treatments. These treatments must have included specific kinds of medications: an ‘immunomodulating agent’, a ‘proteasome inhibitor’, and a ‘CD38 monoclonal antibody’.

There are also some other health requirements. For example, if you've had a stem cell transplant, it must have been more than 100 days ago and you shouldn't have any active infections. Your general health, as measured by a score called 'ECOG performance status', also needs to be at a certain level. The doctors will also need to be able to measure your cancer, for example, by checking certain levels in your blood or urine. You would also need to be healthy in other ways, for example, your heart and eyes would need to be checked carefully.

However, some conditions would mean you couldn't join. For instance, if you have certain eye problems (like current corneal disease, except for very mild cases) or significant heart problems, you wouldn't be able to take part. Also, if you've had a bad reaction to similar drugs in the past, or to any of the ingredients in the study medications, you wouldn't be eligible. The study team will review all your medical information carefully to see if this study is suitable for you.

The detailed involvement for this study isn't fully described in the summary, but typically, taking part in a Phase 1 or 2 trial like this involves regular hospital visits. During these visits, you would have blood tests, physical examinations, and possibly scans to monitor your health and how the treatment is working. You would receive the study medications (belantamab mafodotin and isatuximab) according to a specific schedule. The study would keep a close eye on any side effects you might experience. The total duration of your participation would depend on how your body responds to the treatment and the study's design. There would also be a period of follow-up after your treatment finishes to continue monitoring your health.